ClearPoint Neuro Inc vs UnitedHealth Group Inc — how do they compare? ClearPoint Neuro Inc trades at $15.98 (market cap $478.63M), while UnitedHealth Group Inc trades at $420.11 (market cap $389.68B). The key difference: UnitedHealth Group Inc is far larger — about 814.2× ClearPoint Neuro Inc's market cap, and UnitedHealth Group Inc pays a 2.16% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | UNH | |
|---|---|---|
Market Cap | $478.63M | $389.68B |
Sector | Health | Health |
52-Week High | $29.60 | $431.68 |
52-Week Low | $8.66 | $237.77 |
Enterprise Value | $506.63M | $436.36B |
Dividend Yield | — | 2.16% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
UnitedHealth Group (UNH) trades at $429.09, up 1.05% on the day, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.23 exceeding expectations, and a dividend of $2.32 payable in June 2026. Revenue growth remains robust, reaching $447.57B in 2025, though net margins have compressed to 2.68%.
Outlook is positive due to aging demographics and tech innovation in healthcare, but risks include regulatory scrutiny and margin pressure. Wall Street's average price target of $438.33 suggests modest upside, supported by 82.69% buy ratings. Investors should weigh solid cash flow generation against legal challenges and rising debt levels.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →